Is biotech sentiment as bad as it seems?

For the next Post-Hoc live, I'll be joined by Endpoints Founding Editor John Carroll to talk about his twice-a-year sentiment survey of biotech and pharma execs. The results aren't pretty, and John will put them into perspective against more than half a decade of checking the industry's pulse. We'll also be joined by Senior Reporter Kyle LaHucik, who covers public and private deals, and closely tracks where the money is moving in biotech